First Trust Small Cap Core AlphaDex

Kohl's CFO Sells Common Stock

Praxis Plans to Submit New Drug Application for Essential Tremor Treatment in Q1 2026

Praxis Precision Medicines Stopped Relutrigine's EMBOLD Study Early

Argan Reports Third Quarter Earnings Per Share of $2.17

Zacks Research Upgrades Kohl's Stock Rating to Strong Buy

Panagora Increases Stake in Travere

Argan Expected to Release Q3 2023 Earnings After December 4 Close

Kohl's Reports Q3 Earnings and 2025 Outlook

HC Wainwright Raises Arrowhead Pharmaceuticals' Target Price to $85

Creative Planning and other investors increase holdings in GRAIL stock

Argan, Inc. sees gap-down opening despite strong earnings

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

Arrowhead Pharmaceuticals Director Reports Sale of Company Common Stock

Globalstar Inc. CFO Reports Disposition of Common Stock

Arrowhead Pharmaceuticals to Participate in Multiple Medical Conferences in December 2025 and Present on RNAi Therapies

Arrowhead Pharmaceuticals to Attend Multiple Healthcare Conferences in December 2025 to Showcase Plozasiran Progress

New Jersey Police and Firemen's Retirement System Reduces Kohl's Holdings

B. Riley Maintains Arrowhead Pharmaceuticals 'Strong Buy' Rating, Projects EPS at $6.48

Telsey Advisory Group Downgrades Kohl's EPS Forecast

Argan to Release FY2026 Q3 Earnings on December 4, 2025, After-Market EST; Forecast Revenue USD 264.93 M, EPS USD 1.716

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Tradr 2X Long ASTS Daily ETF

Able View Global

SNSE

VNDA

PRAX

Several healthcare and biotech stocks saw significant gains in after-hours trading on Thursday due to clinical updates, earnings results, and regulatory developments. Sensei Biotherapeutics surged 62.9%, Praxis Precision Medicines rose 24.8%, CooperCompanies climbed 13.0%, Vanda Pharmaceuticals gained 7.5%, Cue Biopharma increased 7.8%, and ResMed added 3.7%. Key drivers included positive clinical trial results, earnings reports, and regulatory decisions.

rttnews

Sensei Biotherapeutics

Vanda Pharma

Praxis Precision Medicines

Resmed

Cue BioPharma

Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed

CDTX

Cidara Therapeutics (NASDAQ:CDTX) reached a new 52-week high, trading at $220.74 with significant volume. Analysts have mixed ratings, with a consensus of "Hold" and a price target of $156.11. The company reported a quarterly EPS of ($1.43), missing estimates. Insider and institutional activities show changes in stock positions. Cidara focuses on developing therapies for serious diseases, including fungal infections.

Market Beat

Cidara Therap

Cidara Therapeutics (NASDAQ:CDTX) Sets New 1-Year High  - Still a Buy?

Kohl's Corp. (KSS) shares fell 1.70% to $22.58 on Thursday, underperforming compared to competitors. The S&P 500 Index rose 0.11%, while the Dow Jones Industrial Average fell 0.07%. This marks the second consecutive day of losses for Kohl's, closing 10.47% below its 52-week high. Trading volume was below the 50-day average.

Dow Jones

Kohls

Kohl's Corp. Stock Underperforms Thursday When Compared To Competitors

Jill Timm, CFO of Kohl’s Corporation, reported the sale of common shares of the company. This information was published via EDGAR by Kohl’s Corporation and is available for public access. The news was generated by Public Technologies using AI and is intended for informational purposes only.

Reuters

Kohl's CFO Jill Timm Reports Sale of Common Shares

Praxis Precision Medicines announced positive results from the EMBOLD study on relutrigine for SCN2A and SCN8A epileptic encephalopathies. The study was stopped early due to efficacy, and results will be presented at the American Epilepsy Society Annual Meeting on December 6, 2025. Praxis plans to meet with the FDA to discuss the study results and potential NDA filing.

Praxis Precision Medicines Reports Positive EMBOLD Study Results for Relutrigine in SCN2A and SCN8A Epileptic Encephalopathies

LQDA

Liquidia Corporation (NASDAQ:LQDA) reached a new 52-week high, trading at $33.42. Analysts have given the stock a consensus rating of "Moderate Buy" with a price target of $38.56. The company reported a significant revenue increase, beating earnings estimates. Insider trading activity includes sales by CFO Michael Kaseta and Director Raman Singh. Institutional investors have modified their holdings, with 64.54% of the stock owned by them.

Liquidia Tech

Liquidia (NASDAQ:LQDA) Hits New 12-Month High  - Here's What Happened

Zacks Research upgraded Kohl's (NYSE:KSS) from a "hold" to a "strong-buy" rating. Other firms have mixed ratings, with Morgan Stanley and JPMorgan giving "underweight" ratings, while Telsey Advisory and Citigroup have more positive outlooks. Kohl's stock opened at $24.75, with a 52-week range of $6.04 to $25.22. The company reported better-than-expected earnings, with a $0.10 EPS for the quarter. Institutional investors have been adjusting their positions in Kohl's stock.

Kohl's (NYSE:KSS) Upgraded at Zacks Research

SKWD

SAIL

Top analysts recommend three 'Strong Buy' stocks: Praxis Precision Medicines (PRAX), Skyward Specialty Insurance Group (SKWD), and SailPoint (SAIL). PRAX has a 70.29% upside, SKWD a 44.31% upside, and SAIL a 40.58% upside. Analysts maintain Buy ratings with adjusted price targets. TipRanks offers tools for real-time analyst rankings and stock insights.

Tip Ranks

Skyward Specialty Insurance

SailPoint

3 'Strong Buy' Stocks to Buy Today, 12/4/2025, According to Top Analysts

TVTX

Panagora Asset Management Inc. increased its stake in Travere Therapeutics by 28.6% in Q2, acquiring 96,062 shares. Analysts have set new price targets for Travere, with Jefferies at $35, Wedbush at $32, and Piper Sandler at $35. Insider trading includes CEO Eric M. Dube selling 92,872 shares. Travere's stock opened at $33.99, with a market cap of $3.04 billion.

Travere Therapeutics

Panagora Asset Management Inc. Buys 96,062 Shares of Travere Therapeutics, Inc. $TVTX

ATEC

Miles Patrick, Chairman of Alphatec Holdings Inc, sold 100,000 shares worth $2.2 million as part of a prearranged trading plan. This transaction was disclosed in a Form 4 filing with the SEC. After the sale, his total holdings are 5,524,978 shares. The sale was executed under a 10b5-1 plan.

Alphatec

Chmn Miles Sells 100,000 ($2.2M) Of Alphatec Holdings Inc [ATEC]

Kohl's Corp. stock fell 7.04% to $22.97 on Wednesday, underperforming compared to competitors like Amazon, Walmart, and Target. Despite a positive trading session for the market, Kohl's closed 8.92% below its 52-week high. Trading volume was higher than average.

Kohl's Corp. Stock Underperforms Wednesday When Compared To Competitors

Christopher R. Cline, CFO of Travere Therapeutics Inc., reported a disposal of common shares. The full filing is available via EDGAR, the U.S. SEC's system. This news brief was created by Public Technologies using AI and is for informational purposes only.

Travere Therapeutics CFO Christopher R. Cline Reports Disposal of Common Shares

LB filings

Kohls | 10-Q: FY2026 Q3 Revenue: USD 3.575 B

Kohl's Q3 net sales fell 2.8% to USD 3.4 billion, with comparable sales down 1.7%. Gross margin improved to 39.6%. SG&A expenses decreased 2.1% to USD 1.3 billion. For 2025, Kohl's expects net sales to decline 3.5%-4% and comparable sales to drop 2.5%-3%. Adjusted operating margin is projected at 3.1%-3.2%, with EPS between USD 1.25 and USD 1.45. Capital expenditures are estimated at USD 400 million. A quarterly dividend of USD 0.125 per share is declared, payable December 24, 2025.

Kohl's Q3 net sales down 2.8% to USD 3.4 billion

Praxis Precision Medicines has granted restricted stock units covering 3,594 shares to six new non-executive employees under its 2024 Inducement Plan. The units will vest in four equal annual installments, contingent on continued employment. This announcement was made via GlobeNewswire on December 03, 2025.

Praxis Precision Medicines Grants Restricted Stock Units to New Employees